NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

數位健康和慢性疾病的管理

Digital Health and the Management of Chronic Disease

出版商 FirstWord 商品編碼 940415
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
數位健康和慢性疾病的管理 Digital Health and the Management of Chronic Disease
出版日期: 2020年06月03日內容資訊: 英文
簡介

COVID-19大流行,促進、提高數位健康的作用,數位平台可能成為通常的 "必需" 的工作方法的轉折點。保險者,HCP,患者,適應數位醫療技術。隨著部門進化,製藥公司可證明可改善慢性疾病的患者的治療結果,聚焦臨床為基礎的先進數位工具。有效的數位解決方案,獲得相關利益者的支持,甚至可能成為法規要求。

需要

本報告提供製藥公司應對數位健康策略所必要的慢性疾病管理相關的具體的問題調查分析,以產業和數位技術的專家採訪的結果為基礎,技術的優先事項與製藥公司想法相關的系統性資訊。

目錄

主題的摘要

調查手法和目的

主要考察的摘要

問題和考察

  • 數位健康的可能性和應對採用之間的差距
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • COVID-19對數位健康的影響
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • 製藥公司的數位健康投資策略的演進
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • 數位健康解決方案的計劃和設計
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • 跟合作夥伴的合作
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
    • 圖表
  • 數位健康解決方案臨床評估
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • 隱私,信賴,採用數位健康的可能性
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • 慢性疾病的預防和自我管理
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
  • 數位治療藥處方的機會
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
    • 圖表
  • 未來的開發機會
    • 問題的摘要
    • 問題
    • 主要考察
    • 引用依據
目錄
Product Code: 596201540

Essential strategies for developing next phase digital health solutions

The COVID-19 pandemic has accelerated and elevated the role of digital health and could serve as a turning point for digital platforms to become the normal "must have" way of working. Payers, HCPs and patients have become comfortable with digital health technology and as the sector evolves pharma is challenged to focus on advanced clinically-based digital tools that can be proven to improve outcomes for patients with chronic diseases. Effective digital solutions will win the support of stakeholders and, in time, may even be a regulatory requirement.

So, what are the specific issues around chronic disease management that pharma needs to address with its digital health strategy? To answer that question we interviewed, in May 2020, expert industry and digital technology specialists. In ‘Digital Health and the Management of Chronic Disease ’ they identify the key payer, patient, physician and technology priorities and touchpoints that should frame pharma's thinking.

Experts explore key questions such as...

  • How have digital business strategies changed as a result of the COVID-19 pandemic?
  • To what extent is pharma's investment and interest moving towards the development of clinical-grade digital solutions that will directly impact patient outcomes?
  • What evidence will stakeholders need in terms of clinical validation data to demonstrate the impact of digital health technologies in specific therapeutic areas?
  • What do companies need to take into account at the planning stage of a new digital solution in terms of feasibility, user desirability/interest and commercial viability?
  • What do developers need to do to ensure that health professionals are willing to prescribe digital therapeutics?

What our experts say...

"First you need to agree with all stakeholders that this is primarily for making sure that people actually get better disease outcomes. That is the number one thing that a digital health solution should target. Also, it costs a lot of money to develop these digital solutions; way less than developing drugs, but there will always be a lot of sceptics in the companies that need to be convinced. Therefore, they need to build a business model and find out how a certain digital tool can either make prescribers prescribe more of your drug, or have preference for your drug, or increase the dose of your drug, or make the patients remember to take their drug, for example." Anders Dyhr Toft.

"I think that the more innovative and thoughtful the company, the more that they are having the innovators, the leaders, and the experts get involved earlier. Most of the time, the right moment to start thinking about digital medicine, digital solutions, is in Phase II and Phase III. If a product is five or six years from being used in patients, a commercially viable digital therapeutic is probably premature. A digital medicine product that could help the clinical trials, that's different because then you're talking about what is actively being deployed during that stage. But I think that, if you have a late stage Phase II product, you should be thinking about your digital medicine strategy. If you have a Phase III, you have to be. And it's not to say that every single product will benefit from a digital medicine companion or correlative product, but at a minimum you need to know if it wouldn't. You should at least answer the question to yourself because if you're not, your competitor is." Ed Cox.

"Instead of making it [the digital solution] a technology driven innovation, we'll make it needs-based innovation. Find out what you need data for [then] find out what technology is geared to cater for that. I often see the opposite. People say, okay, let's do AI. What problems can we solve with that? That is not the right way. That would be my number one key message. And my number two key message is really geared to less work or less burden for the patients. If it's a solution that gives more work to the patient, then it's not going to be a success. And then my last message would be, it has to improve disease outcomes otherwise it's really not worth anything." Anders Dyhr Toft.

What to expect

A detailed report exploring the role and development focus of digital health technologies to improve outcomes for patients suffering from chronic disease:

  • An examination of 10 key issues that impact digital health development strategy and thinking
  • 30 targeted questions put to industry and digital experts
  • Their responses which provided 73 insights supported by 80 directly quoted comments

Expert contributors

Experts contributing to this report have been screened to ensure they have:

  • The ability to provide insights into key digital health developments in their own company, specifically in relation to treating patients with chronic diseases
  • An understanding of the potential for personalized digital solutions to improve patient engagement and health outcomes in chronic disease
  • Knowledge of how digital health solutions can add value for all stakeholders (e.g. through improved adherence to treatment)
  • Knowledge of current trends in the development of digital health solutions aimed at empowering patients and their doctors to better manage chronic disease
  • An understanding of the challenges facing pharma and technology company partnerships working towards realizing digital health ambitions.

Contributors include

  • Eugene Borukhovich , an entrepreneur, venture builder, speaker and board advisor with a focus in digital health. Eugene is a Chairman and Founding Board Member at YourCoach Health and founder of Initium Impact Ventures. Prior to YourCoach, Eugene served as Global Head of Digital Health at Bayer.
  • Ed Cox , the Global Head of Digital Medicine & Executive Vice President, Strategic Alliances at Eversana. Ed was previously CEO at Dthera Sciences. He has served as chair, moderator, or speaker at many other digital therapeutic and digital medicine events throughout the world, including DTxDM, DTx Europe, LSX World Congress and CNS Summit among others.
  • Chandana Fitzgerald , Chief Medical Officer at HealthXL is a medical doctor with work, research and educational experience across European, American and Asian markets. After a brief stint at hospitals, she has engaged extensively in leadership positions in the digital health space to bring innovations that bridge gaps in healthcare.
  • Ron Kamienchick , Senior Director, Commercial Lead, AI and Analytics Products, leading Teva's initiatives around advanced analytics and predictive modelling. Previously, as Senior Director, Digital Health, Head of Diagnostics and Personalized Medicine, he was focused on commercialization efforts for Teva's Connected Respiratory, primarily ProAir and AirDuo Digihaler.
  • Dr Patrick Merel , founder and CEO of Portable Genomics from 2012 to 2019. He also participated in the creation of Edico Genome in 2013, a bioIT genomic company, sold to Illumina in 2018. In 2004-2005 he was consultant for Beckman Coulter to move the company into the molecular diagnostic business. Previously, Patrick had an academic career building and running molecular diagnostic, genetic and genomic clinical settings as well translational research platforms at Bordeaux Blood Bank Center and University Hospital of Bordeaux, France.
  • Joel Sangerman , Chief Commercial Officer at Click Therapeutics. Click created the term Digital Therapeutics in 2012 based on the premise that mobile software can be an effective treatment for people with unmet medical needs. Speaking regularly at major health conferences on how and why Click products are being adopted for population health strategies has led to over 150 healthcare payers using Click's clinically validated digital therapeutics.
  • Cynthia Castro Sweet , PhD, Senior Director of Clinical Research & Policy, Omada Health. Cynthia has a doctorate in clinical psychology with a speciality in behavioural medicine. She was a staff scientist at the Stanford Prevention Research Center for almost two decades managing federally-funded clinical trials of community-based, chronic disease prevention programmes. She left academia in 2015 to join Omada Health and manages Omada's portfolio of research studies to validate the clinical efficacy and economic value of their disease prevention and disease self-management programmes.
  • Anders Dyhr Toft , an experienced leader in the pharmaceutical industry, with an educational background as MD, PhD and eMBA. He has led organizations within Commercial Innovation including Digital Health, Medical Affairs, Clinical Operations, Regulatory, Quality and Safety.
  • Gareth Morinan , Chief Scientific Officer at Machine Medicine, UK.

Why choose FirstWord ExpertViews reports?

FirstWord's ExpertViews reports reveal the real world insights of knowledgeable experts to analyze in detail key commercial and market trends that pharma management need to understand if they are to effectively respond to critical developments. These highly-focussed reports:

  • Are based on primary research with experts whose knowledge and current experience is proven
  • Present clear insights and actionable intelligence
  • Include only the latest primary research and findings-we don't recycle content or pad-out our reports with secondary source material

Table of Contents

Subject synopsis

Research method ology and objectives

  • Methodology
  • Objectives

Key insights summary

Issues and insights

  • Addressing the gaps between digital health potential and adoption
    • Issue summary
    • Question
    • Key insights
    • Supporting quotes
  • Covid-19impact on digital health
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Pharma's evolving digital health investment strategy
    • Issue summary
    • Question
    • Key insights
    • Supporting quotes
  • Planning and designing digital health solutions
    • Issue summary
    • Question
    • Key insights
    • Supporting quotes
  • Working with partners
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Clinical validation of digital health solutions
    • Issue summary
    • Question
    • Key insights
    • Supporting quotes
  • Privacy, trust and willingness to adopt digital health
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Chronic disease prevention and self-management
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Opportunities for prescription digital therapeutics
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence Exhibits
  • Future development opportunities
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes